1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.jchromb.2013.11.048" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jchromb.2013.11.048</a>
Pages
141–146
Volume
945-946
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A quantitative LC-MS/MS method for determination of thiazolidinedione mitoNEET ligand NL-1 in mouse serum suitable for pharmacokinetic studies.
Publisher
An entity responsible for making the resource available
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-01
Subject
The topic of the resource
%CV; %RE; 1-methyl-4-phenyl-1; 2; 3; 3-thiazolidine-2; 4-dione; 5-[3; 5-[4-hydroxy-3; 5-di-tert-butyl-4-hydroxyphenyl)methyl]-1; 5-dimethyl-phenyl)methyl]thiazolidine-2; 6-tetrahydropyridine; Animals; Carry-over; Chromatography; High Pressure Liquid/*methods; internal standard; IS; LC-MS/MS; Limit of Detection; LLOQ; lower limit of quantification; Methanol; Mice; mitoNEET; Mouse serum; MPTP; MRM; multiple reaction monitoring; NL-1; NL-2; percent coefficient of variation; peroxisome proliferator activated receptor-gamma; pharmacokinetic; PK; PPAR-gamma; QC; quality control; relative error; relative matrix effect; RME; SD; standard deviation; Tandem Mass Spectrometry/*methods; thiazolidinedione; Thiazolidinedione (TZD); Thiazolidinediones/*blood; TZD
Creator
An entity primarily responsible for making the resource
Pedada Kiran K; Zhou Xiang; Jogiraju Harini; Carroll Richard T; Geldenhuys Werner J; Lin Li; Anderson David J
Description
An account of the resource
Thiazolidinedione (TZD) compounds have shown promise as antidiabetic, antibiotics, antifungal and neuroprotective agents. The mitochondrial effect of a novel mitoNEET ligand, NL-1 {5-[(3,5-di-tert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione}, and other TZD compounds, is a newly proposed mechanism for the neuroprotective action of these TZD compounds. In this work, a sensitive LC-MS/MS assay has been developed and validated for quantification of NL-1 in mouse serum. Sample preparation involved an acetonitrile protein precipitation procedure with addition of an internal standard NL-2 {5-[(4-hydroxy-3,5-dimethyl-phenyl)methyl]thiazolidine-2,4-dione}. LC-MS/MS analysis utilized a Columbus C-18 HPLC column (2mmx50mm, 5mum). Chromatography employed a multiple step gradient program that featured a steep linear gradient (25-95% in 0.5min) of 15muM ammonium acetate (additive for eliminating carry-over) in 2% methanol mixing with increasing proportions of 100% methanol. The HPLC was interfaced to a QTrap 5500 mass spectrometer (AB Sciex) equipped with an electrospray ionization source used in a negative ionization mode. Multiple reaction monitoring (MRM) of m/z 334–\textgreater263 for NL-1 and m/z 250–\textgreater179 for NL-2 was done. The method had a linear range of at least 1-100ng/mL in serum. The intra-assay and inter-assay percent coefficient of variation (%CV) were less than 4% and accuracies (%RE) ranged from -2.7% to 2.0%. The analytical procedure gave 96-115% absolute extraction recovery of NL-1. The relative matrix effect was measured and found to be insignificant. The analyte in serum was confirmed to be stable during storage and treatment. The method is suitable for pharmacokinetic (PK) studies of the parent drug NL-1 based on the preliminary serum results from dosed NL-1 mouse studies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jchromb.2013.11.048" target="_blank" rel="noreferrer noopener">10.1016/j.jchromb.2013.11.048</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
%CV
%RE
1-Methyl-4-phenyl-1
2
2014
3
3-thiazolidine-2
4-dione
5-[3
5-[4-hydroxy-3
5-di-tert-butyl-4-hydroxyphenyl)methyl]-1
5-dimethyl-phenyl)methyl]thiazolidine-2
6-tetrahydropyridine
Anderson David J
Animals
Carroll Richard T
Carry-over
Chromatography
Department of Internal Medicine
Geldenhuys Werner J
High Pressure Liquid/*methods
internal standard
IS
Jogiraju Harini
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
LC-MS/MS
Limit of Detection
Lin Li
LLOQ
lower limit of quantification
Methanol
Mice
mitoNEET
Mouse serum
MPTP
MRM
multiple reaction monitoring
NEOMED College of Medicine
NL-1
NL-2
Pedada Kiran K
percent coefficient of variation
peroxisome proliferator activated receptor-gamma
pharmacokinetic
PK
PPAR-gamma
QC
Quality Control
relative error
relative matrix effect
RME
SD
standard deviation
Tandem Mass Spectrometry/*methods
thiazolidinedione
Thiazolidinedione (TZD)
Thiazolidinediones/*blood
TZD
Zhou Xiang
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/b978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/b978-0-12-386467-3.00006-6</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
107-125
Volume
100
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
MULTIMODAL DRUGS AND THEIR FUTURE FOR ALZHEIMER'S AND PARKINSON'S DISEASE
Publisher
An entity responsible for making the resource available
Monoamine Oxidases and Their Inhibitors
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011
Subject
The topic of the resource
designed multiple ligands; gamma agonist; inflammatory response; ischemia-reperfusion injury; mitochondrial-membrane protein; monoamine-oxidase-b; multifunctional drugs; neurodegenerative disorders; pioglitazone; ppar-gamma; receptor antagonist
Creator
An entity primarily responsible for making the resource
Van der Schyf C J; Geldenhuys W J
Description
An account of the resource
This chapter discusses the rationale for developing multimodal or multifunctional drugs (also called designed multiple ligands or DMLs) aimed at disease-modifying treatment strategies for the most common neurodegenerative diseases Alzheimer's and Parkinson's disease (AD and PD). Both the prevalence and incidence of AD and PD have seen consistent and dramatic increases, a disconcerting phenomenon which, ironically, has been attributed to extended life expectancy brought about by better health care globally. In spite of these statistics, the development and introduction to the clinic of new therapies proven to prevent or delay the onset of AD and PD have been disappointing. Evidence has accumulated to suggest that the etiopathology of these diseases is extremely complex, with an array of potential drug targets located within a number of deleterious biochemical pathways. Therefore, in these diseases, it is unlikely that the complex pathoetiological cascade leading to disease initiation or progression will be mitigated by any one drug acting on a single pathway or target. The pursuit of novel DMLs may offer far better outcomes. Although certainly not the only, and perhaps not even the best, approach but farthest along the drug development pipeline in the DML paradigm are drugs that combine inhibition of monoamine oxidase with associated etiological targets unique to either AD or PD. These compounds will constitute the major focus of this chapter, which will also explore radically new paradigms that seek to combine cognitive enhancers with proneurogenesis compounds.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/b978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">10.1016/b978-0-12-386467-3.00006-6</a>
Format
The file format, physical medium, or dimensions of the resource
Book Section
2011
Book Section
designed multiple ligands
gamma agonist
Geldenhuys W J
inflammatory response
ischemia-reperfusion injury
mitochondrial-membrane protein
Monoamine Oxidases and Their Inhibitors
monoamine-oxidase-b
Multifunctional drugs
neurodegenerative disorders
pioglitazone
PPAR-gamma
receptor antagonist
Van der Schyf C J